Overall rank by patents
#24,497
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 15 technology areas, active 2016–2018. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: H04M (TELEPHONIC COMMUNICATION).
The verdict
I-blades holds 11 US patents across 15 technology areas, rank #24,497 of 50,000 tracked assignees.
I-blades, Inc. has been granted 11 US utility patents between 2016 and 2018, placing I-blades, Inc. at rank #24,497 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.2 claims per patent with primary concentration in H04M (TELEPHONIC COMMUNICATION). As a US Corporation, I-blades, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, I-blades sits between Hurley International Llc (11 patents, rank #24,493) and I.g. Cardboard Technologies Ltd. (11 patents, rank #24,501) - the closest US assignees by grant volume. The composite Innovation Score of 30.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 11 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. I-blades, Inc.'s 14.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark I-blades, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Hurley International LLC
11 patents
Hybio Pharmaceutical Co., Ltd.
11 patents
Hydro Aluminium Deutschland GmbH
11 patents
Hyster-Yale Materials Handling, Inc.
11 patents
I-INTERACTIVE LLC
11 patents
I-JACK TECHNOLOGIES INCORPORATED
11 patents
I.E.R.
11 patents
I.G. CARDBOARD TECHNOLOGIES LTD.
11 patents
I-BLADES, INC.
11 patents
What this shows I-blades holds 11 patents at rank #24,497, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
I-blades's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 64% higher than 36% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 9.1% |
| 2017 | 6 | 54.5% |
| 2018 | 4 | 36.4% |
Top 15 of 15 technology areas
Overall rank by patents
#24,497
Across all tracked assignees
30.8 out of 100
How to use this portfolio
I-blades's 11 grants land it in the top 64% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.